Vera Therapeutics, Inc. (VERA) FY2025 10-K Annual Report
Vera Therapeutics, Inc. (VERA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Vera Therapeutics, Inc. FY2025 10-K Analysis
Risk Factors
- • Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
- • Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments
Vera Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$300M
▼ -96.9% YoY
ROE
-49.6%
▼ -2320bp YoY
Total Assets
$735M
▲ +12.1% YoY
EPS (Diluted)
$-4.66
▼ -69.5% YoY
Operating Cash Flow
-$241M
▼ -79.0% YoY
Source: XBRL data from Vera Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.